Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | TARDBP | Q13148 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3676279 | 1.00 | KMT2A (0.41) | KMT2AALOX15BLMPMP22DPP4 | |
| SCHEMBL1509587 | 0.98 | KMT2A (0.42) | KMT2AALOX15BLMPMP22DPP4 | |
| SCHEMBL1509586 | 0.98 | KMT2A (0.42) | KMT2AALOX15BLMPMP22DPP4 | |
| SCHEMBL4952904 | 0.86 | GRM8 (0.43) | BLMDPP4DPP8DPP9 | |
| SCHEMBL4952914 | 0.86 | GRM8 (0.43) | BLMDPP4DPP8DPP9 | |
| SCHEMBL6753730 | 0.79 | GSR (0.43) | DPP4DPP8DPP9 | |
| SCHEMBL902368 | 0.78 | PTGS1 (0.36) | — | |
| SCHEMBL27662491 | 0.74 | ALOX15 (0.39) | KMT2AALOX15BLMPMP22DPP4 | |
| Hydrochloric Acid SCHEMBL6098929 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL5706355 | 0.70 | DPP4 (0.40) | DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216800-A1 | Treatment of Type 2 Diabetes With a Combination of DPIV Inhibitor and Metformin or Thiazolidinedione | ROYALTY PHARMA FINANCE TRUST | 2010-08-26 | — | — | US | claimed |
| US-20090186818-A1 | Therapeutic Method for Glycaemic Control | PROSIDION LIMITED (GB) | 2009-07-23 | — | — | US | claimed |
| EP-2010217-A2 | THERAPEUTIC METHOD FOR GLYCAEMIC CONTROL | Prosidion Limited (GB) | 2009-01-07 | — | — | EP | claimed |
| EP-1965783-A1 | TREATMENT OF TYPE 2 DIABETES WITH A COMBINATION OF DPIV INHIBITOR AND METFORMIN OR THIAZOLIDINEDIONE | Prosidion Limited (GB) | 2008-09-10 | — | — | EP | claimed |
| WO-2007122419-A2 | THERAPEUTIC METHOD FOR GLYCAEMIC CONTROL | PROSIDION LIMITED (GB) | 2007-11-01 | — | — | WO | claimed |
| WO-2007072083-A1 | TREATMENT OF TYPE 2 DIABETES WITH A COMBINATION OF DPIV INHIBITOR AND METFORMIN OR THIAZOLIDINEDIONE | PROSIDION LIMITED (GB) | 2007-06-28 | — | — | WO | claimed |
| US-20060287251-A1 | Combination therapy for glycaemic control | DEMUTH HANS-ULRICH | 2006-12-21 | — | — | US | claimed |
| EP-1695970-A1 | Peptides useful for competitive modulation of dipeptidyl peptidase IV catalysis | Prosidion Limited (GB) | 2006-08-30 | — | — | EP | claimed |
| EP-1663200-A2 | COMBINATION THERAPY FOR GLYCAEMIC CONTROL | Prosidion Limited (GB) | 2006-06-07 | — | — | EP | claimed |
| WO-2005020983-A2 | COMBINATION THERAPY FOR GLYCAEMIC CONTROL | PROSIDION LTD. (GB) | 2005-03-10 | — | — | WO | claimed |
| EP-1399471-B1 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2008-01-30 | — | — | EP | disclosed |
| CN-1321682-C | New dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents | PROBIODRUG AG (DE) | 2007-06-20 | — | — | CN | disclosed |
| EP-1480961-B1 | GLUTAMINYL BASED DPIV INHIBITORS | PROSIDION LTD (GB) | 2006-12-27 | — | — | EP | disclosed |
| US-20060287251-A1 | Combination therapy for glycaemic control | DEMUTH HANS-ULRICH | 2006-12-21 | — | — | US | disclosed |
| EP-1695970-A1 | Peptides useful for competitive modulation of dipeptidyl peptidase IV catalysis | Prosidion Limited (GB) | 2006-08-30 | — | — | EP | disclosed |
| WO-2003072556-A1 | GLUTAMINYL BASED DPIV INHIBITORS | PROSIDION LTD. (GB) | 2003-09-04 | — | — | WO | disclosed |
| US-20030130199-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | PROBIODRUG (DE) | 2003-07-10 | — | — | US | disclosed |
| WO-2003015775-A1 | NEW DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES FOR LOWERING BLOOD PRESSURE LEVELS | PROBIODRUG AG (DE) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003002596-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002595-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES AS ANTI-CANCER AGENTS | PROBIODRUG AG (DE) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287251-A1 | Combination therapy for glycaemic control | IAPP, SLC5A2, GCG | DPP4 16/4885KMT2A 2983/4885ALOX15 2662/4885 |
| US-20030130199-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | DPP4, DPP3, DNPEP | DPP4 1/4885KMT2A 2238/4885ALOX15 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.